WallStSmart

Laboratory Corporation of America Holdings (LH)vsNovartis AG ADR (NVS)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Novartis AG ADR generates 301% more annual revenue ($56.69B vs $14.14B). NVS leads profitability with a 22.5% profit margin vs 6.7%. LH appears more attractively valued with a PEG of 1.20. LH earns a higher WallStSmart Score of 67/100 (B-).

LH

Strong Buy

67

out of 100

Grade: B-

Growth: 7.3Profit: 5.5Value: 4.7Quality: 6.5
Piotroski: 5/9Altman Z: 2.26

NVS

Buy

51

out of 100

Grade: C-

Growth: 4.0Profit: 9.0Value: 3.3Quality: 4.5
Piotroski: 4/9Altman Z: 1.96
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

LHSignificantly Overvalued (-38.6%)

Margin of Safety

-38.6%

Fair Value

$209.18

Current Price

$307.15

$97.97 premium

UndervaluedFair: $209.18Overvalued
NVSSignificantly Overvalued (-68.7%)

Margin of Safety

-68.7%

Fair Value

$92.54

Current Price

$159.85

$67.31 premium

UndervaluedFair: $92.54Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

LH2 strengths · Avg: 8.0/10
Price/BookValuation
2.9x8/10

Reasonable price relative to book value

EPS GrowthGrowth
32.9%8/10

Earnings expanding 32.9% YoY

NVS5 strengths · Avg: 9.4/10
Market CapQuality
$290.96B10/10

Mega-cap, among the largest globally

Return on EquityProfitability
35.1%10/10

Every $100 of equity generates 35 in profit

Operating MarginProfitability
31.8%10/10

Strong operational efficiency at 31.8%

Profit MarginProfitability
22.5%9/10

Keeps 23 of every $100 in revenue as profit

Free Cash FlowQuality
$2.87B8/10

Generating 2.9B in free cash flow

Areas to Watch

LH2 concerns · Avg: 3.5/10
P/E RatioValuation
25.1x4/10

Moderate valuation

Profit MarginProfitability
6.7%3/10

6.7% margin — thin

NVS4 concerns · Avg: 3.3/10
Revenue GrowthGrowth
0.8%4/10

0.8% revenue growth

Altman Z-ScoreHealth
1.964/10

Grey zone — moderate risk

Debt/EquityHealth
1.223/10

Elevated debt levels

PEG RatioValuation
4.152/10

Expensive relative to growth rate

Comparative Analysis Report

WallStSmart Research

Bull Case : LH

The strongest argument for LH centers on Price/Book, EPS Growth. PEG of 1.20 suggests the stock is reasonably priced for its growth.

Bull Case : NVS

The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 22.5% and operating margin at 31.8%.

Bear Case : LH

The primary concerns for LH are P/E Ratio, Profit Margin.

Bear Case : NVS

The primary concerns for NVS are Revenue Growth, Altman Z-Score, Debt/Equity.

Key Dynamics to Monitor

LH carries more volatility with a beta of 0.86 — expect wider price swings.

LH is growing revenue faster at 5.8% — sustainability is the question.

NVS generates stronger free cash flow (2.9B), providing more financial flexibility.

Monitor DIAGNOSTICS & RESEARCH industry trends, competitive dynamics, and regulatory changes.

Bottom Line

LH scores higher overall (67/100 vs 51/100). Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Laboratory Corporation of America Holdings

HEALTHCARE · DIAGNOSTICS & RESEARCH · USA

Laboratory Corporation of America Holdings, more commonly known as Labcorp, is an American company headquartered in Burlington, North Carolina. It operates one of the largest clinical laboratory networks in the world, with a United States network of 36 primary laboratories.

Visit Website →

Novartis AG ADR

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.

Visit Website →

Want to dig deeper into these stocks?